Sustained accumulation of microtubule-binding chemotherapy drugs in the peripheral nervous system: Correlations with time course and neurotoxic severity

Cancer Research

Volumn 76, Issue 11, 2016, Pages 3332-3339

  Wozniak, Krystyna M ^a   Vornov, James J ^b   Wu, Ying ^a   Nomoto, Kenichi ^c   Littlefield, Bruce A ^c   DesJardins, Christopher ^c   Yu, Yanke ^c   Lai, George ^c   Reyderman, Larisa ^c   Wong, Nancy ^c   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medpace ^*  (United States)

^c EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERIBULIN; IXABEPILONE; PACLITAXEL; EPOTHILONE DERIVATIVE; FURAN DERIVATIVE; KETONE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NERVE CONDUCTION VELOCITY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SCIATIC NERVE; SPINAL GANGLION; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; ELECTROPHYSIOLOGY; METABOLISM; MICROTUBULE; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM DISEASES; TIME FACTOR; TISSUE DISTRIBUTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; EPOTHILONES; FEMALE; FURANS; GANGLIA, SPINAL; KETONES; MICE; MICE, INBRED BALB C; MICROTUBULES; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; SCIATIC NERVE; TIME FACTORS; TISSUE DISTRIBUTION; TUBULIN MODULATORS;

EID: 84975091261     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2525     Document Type: Article

References (48)

1. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011;11:73-81.
2. Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011;10:407-17.
3. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, et al. Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 2011;71:3952-62.
4. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012;203:194-206.
5. Bennett GJ, Liu GK, Xiao WH, Jin HW, Siau C. Terminal arbor degeneration-a novel lesion produced by the antineoplastic agent paclitaxel. Eur J Neurosci 2011;33:1667-76.
6. Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232:154-61.
7. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150-61.
8. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012;82:51-77.
9. Li Y, Chen N, Palmisano M, Zhou S. Pharmacologic sensitivity of paclitaxel to its delivery vehicles drives distinct clinical outcomes of paclitaxel formulations. Mol Pharm 2015;12:1308-17.
10. Li P, Albrecht BJ, Yan X, Gao M, Weng HR, Bartlett MG. A rapid analytical method forthe quantification of paclitaxel in rat plasma and brain tissue by high-performance liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom 2013;27:2127-34.
11. Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, et al. Influence of drug formulation on OATP1B-mediated transport of paclitaxel. Cancer Res 2014;74:3137-45.
12. Wang Y, Liu J, Zhang J, Wang L, Chan J, Wang H, et al. A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs. Int J Med Sci 2014;11:479-87.
13. Taur JS, DesJardins CS, Schuck EL, Wong YN. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 2011;41:320-6.
14. Gallo JM, Li S, Guo P, Reed K, Ma J. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Res 2003;63:5114-7.
15. Mortier KA, Renard V, Verstraete AG, Van Gussem A, Van Belle S, Lambert WE. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid. Anal Chem 2005;77:4677-83.
16. Desjardins C, Saxton P, Lu SX, Li X, Rowbottom C, Wong YN. A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008;875:373-82.
17. Xu XS, Zeng J, Mylott W, Arnold M, Waltrip J, Iacono L, et al. Liquid chromatography and tandem mass spectrometry for the quantitative determination of ixabepilone (BMS-247550, Ixempra) in human plasma: method validation, overcoming curve splitting issues and eliminating chromatographic interferences from degradants. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:525-37.
18. Wozniak KM, Wu Y, Farah MH, Littlefield BA, Nomoto K, Slusher BS. Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy. Neurotox Res 2013;24:338-44.
19. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, et al. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 2010;100:261-8.
20. Andersen A, Warren DJ, Brunsvig PF, Aamdal S, Kristensen GB, Olsen H. High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection. BMC Clin Pharmacol 2006;6:2.
21. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
22. Cavaletti G, Cavalletti E, Oggioni N, Sottani C, Minoia C, D'Incalci M, et al. Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology 2000;21:389-93.
23. Jang SH, Wientjes MG, Au JL. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001;298:1236-42.
24. Au JL, Li D, Gan Y, Gao X, Johnson AL, Johnston J, et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998;58:2141-8.
25. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol 2006;17:735-49.
26. Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions. Neuropharmacology 2014;76:175-83.
27. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
28. Sprowl JA, Sparreboom A. Uptake carriers and oncology drug safety. Drug Metab Dispos 2014;42:611-22.
29. Sissung TM, Reece KM, Spencer S, Figg WD. Contribution of the OATP1B subfamily to cancer biology and treatment. Clin Pharmacol Ther 2012;92:658-60.
30. Kuh HJ, Jang SH, Wientjes MG, Au JL. Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther 2000;293:761-70.
31. Fransson MN, Brugard J, Aronsson P, Green H. Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics. Eur J Pharm Sci 2012;47:759-67.
32. Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008;13:214-21.
33. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95.
34. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013;37:231-9.
35. O'Rourke B, Yang CP, Sharp D, Horwitz SB. Eribulin disrupts EB1-microtubule plus-tip complex formation. Cell Cycle 2014;13:3218-21.
36. Jang SH, Wientjes MG, Au JL. Interdependent effect of P-glycoprotein-mediated drug efflux and intracellular drug binding on intracellular paclitaxel pharmacokinetics: application of computational modeling. J Pharmacol Exp Ther 2003;304:773-80.
37. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50.
38. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, et al. Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 1995;87:1077-81.
39. Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, et al. Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model. Bioorg Med Chem Lett 2011;21:1639-43.
40. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 2002;110:1309-18.
41. Sano Y, Shimizu F, Nakayama H, Abe M, Maeda T, Ohtsuki S, et al. Endothelial cells constituting blood-nerve barrier have highly specialized characteristics as barrier-forming cells. Cell Struct Funct 2007;32:139-47.
42. Yosef N, Ubogu EE. An immortalized human blood-nerve barrier endothelial cell line for in vitro permeability studies. Cell Mol Neurobiol 2013;33:175-86.
43. Abram SE, Yi J, Fuchs A, Hogan QH. Permeability of injured and intact peripheral nerves and dorsal root ganglia. Anesthesiology 2006;105:146-53.
44. Benbow SJ, Cook BM, Reifert J, Wozniak KM, Slusher BS, Littlefield BA, et al. Effects of paclitaxel and eribulin in mouse sciatic nerve: a microtubule-based rationale for the differential induction of chemotherapy-induced peripheral neuropathy. Neurotox Res 2016;29:299-313.
45. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, et al. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009;6:620-9.
46. Perez EA.Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
47. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7.
48. Dumontet C, Sikic BI. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.